ATP7A and non-small cell lung carcinoma: These results indicated that ATP7A expression assessed by immunohistochemistry could be a chemo-resistant marker and a negative prognostic factor for survival in NSCLC patients treated with platinum-based chemotherapy, providing a basis for a better utilization of platinum-based antitumor agents and thereby improving the survival of NSCLC patients.